Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WNT3A | P56704 | 4/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.50 |
| ▸ | GALR3 | O60755 | 2/20 | 0.50 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477749 | 0.95 | EGFR (0.57) | WNT3AEGFRNR2F2GALR3UTS2R | |
| SCHEMBL31098952 | 0.95 | EGFR (0.57) | WNT3AEGFRNR2F2GALR3UTS2R | |
| Methane SCHEMBL9378754 | 0.93 | EGFR (0.55) | WNT3AEGFRNR2F2GALR3UTS2R | |
| SCHEMBL10055013 | 0.92 | WNT3A (0.48) | WNT3AEGFRNR2F2GALR3UTS2R | |
| SCHEMBL509566 | 0.88 | EGFR (0.64) | EGFRNR2F2MAPK1KMT2AKDM4E | |
| SCHEMBL29647714 | 0.85 | HDAC6 (0.62) | — | |
| SCHEMBL19631286 | 0.85 | HDAC6 (0.62) | — | |
| SCHEMBL9927462 | 0.84 | CYP1A2 (0.56) | EGFRRAB9ALMNATSHRMAPK1 | |
| SCHEMBL19631284 | 0.84 | MAPT (0.53) | EGFRSMN1; SMN2KMT2AKDM4EALDH1A1 | |
| SCHEMBL8370748 | 0.82 | AURKA (0.52) | WNT3AEGFRUTS2RGRM4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2023-10-10 | — | — | US | disclosed |
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2021-12-30 | — | — | US | disclosed |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2020-04-28 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | EMORY UNIVERSITY | 2018-04-19 | — | — | US | disclosed |
| EP-2776387-B1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | UNIV EMORY (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | METASTATIX, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | EMORY UNIVERSITY | 2016-01-07 | — | — | US | disclosed |
| US-9205085-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | EMORY UNIVERSITY (US) | 2015-12-08 | — | — | US | disclosed |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY | 2014-02-06 | — | — | US | disclosed |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | EMORY UNIVERSITY | 2014-02-06 | — | — | US | disclosed |
| WO-2013070660-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | EMORY UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114884-B2 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008312-B2 | CXCR4 antagonists for the treatment of HIV infection | EMORY UNIVERSITY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | EMORY UNIVERSITY | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401836-A1 | TRICYCLIC AMINO CONTAINING COMPOUNDS FOR TREATMENT OR PREVENTION OF SYMPTOMS ASSOCIATED WITH ENDOCRINE DYSFUNCTION | SHBG, ABAT, GLS | WNT3A 4771/4885EGFR 3060/4885NR2F2 3951/4885 |
| US-10632120-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | WNT3A 4771/4885EGFR 3060/4885NR2F2 3951/4885 |
| US-20070054930-A1 | CXCR4 antagonists for the treatment of medical disorders | CXCR4, CXCL12, CXCR1 | WNT3A 691/4885EGFR 645/4885NR2F2 345/4885 |
| US-20160058761-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | WNT3A 4771/4885EGFR 3060/4885NR2F2 3951/4885 |
| US-11779583-B2 | Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction | SHBG, ABAT, GLS | WNT3A 4771/4885EGFR 3060/4885NR2F2 3951/4885 |
| US-20160002174-A1 | CXCR4 Antagonists for the Treatment of Medical Disorders | CXCR4, CXCL12, CXCR1 | WNT3A 691/4885EGFR 645/4885NR2F2 345/4885 |
| US-20140039187-A1 | CXCR4 ANTAGONISTS FOR THE TREATMENT OF MEDICAL DISORDERS | CXCR4, CXCL12, CXCR1 | WNT3A 691/4885EGFR 645/4885NR2F2 345/4885 |
| US-20180104243-A1 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction | SHBG, ABAT, GLS | WNT3A 4771/4885EGFR 3060/4885NR2F2 3951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.